Evaluating the antifracture efficacy of bisphosphonates

Area of Science:

• Pharmacology
• Bone Metabolism
• Clinical Therapeutics

Background:

• Bisphosphonate (BP) dosing has evolved from daily oral to weekly, monthly oral, and infrequent intravenous (IV) regimens.
• Comparative fracture efficacy among different bisphosphonate options is a growing clinical concern.
• Bridging trials and observational studies are used to assess the efficacy of newer, less frequent bisphosphonate regimens.

Purpose of the Study:

• To review the key efficacy data for currently available bisphosphonates (BPs), including their nondaily regimens.
• To assist clinicians in assessing treatment options for the prevention of nonvertebral fractures (NVFs).

Main Methods:

• Review of available clinical trial and meta-analysis evidence for bisphosphonate efficacy.
• Analysis of data from bridging trials comparing nondaily regimens to daily regimens.
• Consideration of observational studies and the concept of annual cumulative exposure for efficacy assessment.

Main Results:

• All approved bisphosphonate regimens, including nondaily oral and annual IV infusions, have demonstrated effective reduction of vertebral fractures.
• Evidence supports the efficacy of all approved BP regimens in reducing nonvertebral fractures (NVFs), though results varied in initial trials.
• Head-to-head trials directly comparing bisphosphonate antifracture efficacy are limited due to logistical and cost constraints.

Conclusions:

• Current evidence supports the effectiveness of all approved bisphosphonate regimens in reducing both vertebral and nonvertebral fractures.
• Nondaily bisphosphonate regimens offer a viable and effective alternative to daily dosing.
• Clinicians can utilize comprehensive efficacy data to guide bisphosphonate treatment choices for fracture prevention.